share_log

NETRAMARK ANNOUNCES SHARES FOR DEBT SETTLEMENT

NETRAMARK ANNOUNCES SHARES FOR DEBT SETTLEMENT

NETRAMARK 宣佈股票用於債務清算
PR Newswire ·  2023/07/06 06:36

TORONTO, July 5, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) announces that it has entered into debt settlement agreements with certain consultants, pursuant to which the Company has agreed to settle an aggregate amount of $240,000 in outstanding debt in exchange for the issuance of 600,000 common shares in the capital of the Company (the "Common Shares") at a deemed price of $0.40 per share (the "Debt Settlement"). Pursuant to the policies of the Canadian Securities Exchange, the Debt Settlement cannot close prior to five business days from the date of this announcement.

多倫多,2023年7月5日NetraMark控股公司(“公司”或“NetraMark”)(CSE:AIAI)(OTCQB:AINMF)(法蘭克福證券交易所股票代碼:8TV)宣佈,已與若干顧問公司達成債務清償協定,根據該協定,公司同意清償總額為240,000美元的未償債務,以換取以每股0.4美元的價格發行600,000股公司股本中的普通股(“普通股”)(“債務清償”)。根據加拿大證券交易所的政策,債務結算不得在本公告發布之日起五個工作日內完成。

The Common Shares issued in connection with the Debt Settlement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

根據適用的證券法規,與債務清償相關而發行的普通股將受四個月的法定持有期外加自發行之日起一天的限制。

About NetraMark

關於NetraMark

NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.

NetraMark是一家專注於成為針對製藥行業的人工智慧(AI)/機器學習(ML)解決方案開發的領先者的公司。它的產品使用了一種新的基於拓撲的算法,該算法能夠將患者數據集解析為同時根據幾個變量緊密相關的人的子集。這允許NetraMark根據數據的特徵和大小使用各種ML方法,將數據轉換為激活傳統AI/ML方法的強大智慧數據。其結果是,NetraMark可以處理小得多的數據集,並準確地將疾病劃分為不同的類型,以及根據藥物敏感性和/或治療效果對患者進行準確分類。

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).

欲瞭解本公司的更多詳情,請參閱本公司在電子檔案分析和檢索系統(SEDAR)上存檔的公開檔案。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論